{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T01:15:31Z","timestamp":1788138931800,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd015824","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000}}],"reference-count":63,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd015824.pub2","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T10:58:49Z","timestamp":1754305129000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Phosphodiesterase type 5 inhibitor plus endothelin receptor antagonist compared to either alone for group 1 pulmonary arterial hypertension"],"prefix":"10.1002","volume":"2025","author":[{"given":"Yuji","family":"Oba","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine; University of Missouri; Columbia Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tinashe","family":"Maduke","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine; University of Missouri; Columbia Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eddie W","family":"Fakhouri","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine; University of Missouri; Columbia Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohannes","family":"Goite","sequence":"additional","affiliation":[{"name":"Valley Health Pulmonary and Sleep Specialists; Winchester Medical Center; Winchester Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"key":"10.1002\/14651858.CD015824.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"f2304","DOI":"10.1136\/bmj.f2304","article-title":"Influence of trial sample size on treatment effect estimates: meta-epidemiological study","volume":"346","author":"Dechartres","year":"2013","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD015824.pub2-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"1801904","DOI":"10.1183\/13993003.01904-2018","article-title":"Diagnosis of pulmonary hypertension","volume":"53","author":"Frost","year":"2019","journal-title":"European Respiratory Journal"},{"issue":"162","key":"10.1002\/14651858.CD015824.pub2-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"200330","DOI":"10.1183\/16000617.0330-2020","article-title":"Sex and gender in pulmonary arterial hypertension","volume":"30","author":"Cheron","year":"2021","journal-title":"European Respiratory Review"},{"issue":"1","key":"10.1002\/14651858.CD015824.pub2-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"1801887","DOI":"10.1183\/13993003.01887-2018","article-title":"Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives","volume":"53","author":"Humbert","year":"2019","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD015824.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"j5492","DOI":"10.1136\/bmj.j5492","article-title":"Pulmonary arterial hypertension: pathogenesis and clinical management","volume":"360","author":"Thenappan","year":"2018","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD015824.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"1801913","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"European Respiratory Journal"},{"issue":"12","key":"10.1002\/14651858.CD015824.pub2-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1161\/01.cir.0000029100.82385.58","article-title":"Survival in primary pulmonary hypertension: the impact of epoprostenol therapy","volume":"106","author":"McLaughlin","year":"2002","journal-title":"Circulation"},{"issue":"38","key":"10.1002\/14651858.CD015824.pub2-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"European Heart Journal"},{"issue":"2","key":"10.1002\/14651858.CD015824.pub2-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"1700740","DOI":"10.1183\/13993003.00740-2017","article-title":"Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model","volume":"50","author":"Hoeper","year":"2017","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD015824.pub2-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S2213-2600(16)00027-8","article-title":"Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis","volume":"4","author":"Lajoie","year":"2016","journal-title":"Lancet Respiratory Medicine"},{"issue":"3","key":"10.1002\/14651858.CD015824.pub2-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2217\/fca.13.6","article-title":"Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics","volume":"9","author":"Duarte","year":"2013","journal-title":"Future Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD015824.pub2-BIB0012|cit12","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012621.pub2","article-title":"Phosphodiesterase 5 inhibitors for pulmonary hypertension","author":"Barnes","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD015824.pub2-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.37765\/ajmc.2021.88610","article-title":"The evolving treatment landscape of pulmonary arterial hypertension","volume":"27","author":"Gale","year":"2021","journal-title":"American Journal of Managed Care"},{"issue":"3","key":"10.1002\/14651858.CD015824.pub2-BIB0014|cit14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004434.pub5","article-title":"Endothelin receptor antagonists for pulmonary arterial hypertension","author":"Liu","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD015824.pub2-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1183\/13993003.02043-2015","article-title":"Initial dual oral combination therapy in pulmonary arterial hypertension","volume":"47","author":"Sitbon","year":"2016","journal-title":"European Respiratory Journal"},{"issue":"9","key":"10.1002\/14651858.CD015824.pub2-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension","volume":"373","author":"Gali\u00e8","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD015824.pub2-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S2213-2600(16)30019-4","article-title":"Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised long-term extension trial","volume":"4","author":"Ghofrani","year":"2016","journal-title":"Lancet Respiratory Medicine"},{"issue":"5","key":"10.1002\/14651858.CD015824.pub2-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1183\/09031936.00090614","article-title":"Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2)","volume":"45","author":"Rubin","year":"2015","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD015824.pub2-BIB0019|cit19","unstructured":"Higgins JP Lasserson T Chandler J Tovey D Churchill R Methodological Expectations of Cochrane Intervention Reviews Available from https:\/\/community.cochrane.org\/mecir-manual"},{"key":"10.1002\/14651858.CD015824.pub2-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD015824.pub2-BIB0021|cit21","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015824","article-title":"Phosphodiesterase type 5 inhibitor plus endothelin receptor antagonist compared to either alone for group 1 pulmonary arterial hypertension","author":"Oba","year":"2024","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD015824.pub2-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1164\/rccm.202208-1547OC","article-title":"Minimal clinically important difference in the 6-minute walk distance for patients with pulmonary arterial hypertension","volume":"207","author":"Moutchia","year":"2023","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"6","key":"10.1002\/14651858.CD015824.pub2-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1513\/AnnalsATS.201512-824OC","article-title":"The minimal important difference in Borg Dyspnea Score in pulmonary arterial hypertension","volume":"13","author":"Khair","year":"2016","journal-title":"Annals of the American Thoracic Society"},{"key":"10.1002\/14651858.CD015824.pub2-BIB0024|cit24","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Marshall C Technical Supplement to Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston MS, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.3"},{"issue":"7","key":"10.1002\/14651858.CD015824.pub2-BIB0025|cit25","first-page":"e1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"Public Library of Science Medicine"},{"key":"10.1002\/14651858.CD015824.pub2-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1056\/NEJMsm1605385","article-title":"Per-protocol analyses of pragmatic trials","volume":"377","author":"Hern\u00e1n","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015824.pub2-BIB0027|cit27","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2024"},{"key":"10.1002\/14651858.CD015824.pub2-BIB0028|cit28","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.3"},{"key":"10.1002\/14651858.CD015824.pub2-BIB0029|cit29","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.2"},{"key":"10.1002\/14651858.CD015824.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015824.pub2-BIB0031|cit31","unstructured":"RoB 2 tool Available at https:\/\/www.riskofbias.info\/welcome\/rob-2-0-tool"},{"key":"10.1002\/14651858.CD015824.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"c3515","DOI":"10.1136\/bmj.c3515","article-title":"Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study","volume":"342","author":"N\u00fcesch","year":"2010","journal-title":"BMJ"},{"issue":"7","key":"10.1002\/14651858.CD015824.pub2-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1177\/21925682221110527","article-title":"Fixed-effect vs random-effects models for meta-analysis: 3 points to consider","volume":"12","author":"Dettori","year":"2022","journal-title":"Global Spine Journal"},{"key":"10.1002\/14651858.CD015824.pub2-BIB0034|cit34","unstructured":"McKenzie JE Brennan SE Chapter 12: Synthesizing and presenting findings using other methods. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.4"},{"key":"10.1002\/14651858.CD015824.pub2-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jclinepi.2023.03.003","article-title":"GRADE guidance 36: updates to GRADE's approach to addressing inconsistency","volume":"158","author":"Guyatt","year":"2023","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015824.pub2-BIB0036|cit36","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.4"},{"key":"10.1002\/14651858.CD015824.pub2-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"e8668","DOI":"10.1136\/bmj.e8668","article-title":"Differential dropout and bias in randomised controlled trials: when it matters and when it may not","volume":"346","author":"Bell","year":"2013","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD015824.pub2-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction \u2013 GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015824.pub2-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jclinepi.2022.07.014","article-title":"GRADE Guidance 34: update on rating imprecision using a minimally contextualized approach","volume":"150","author":"Zeng","year":"2022","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015824.pub2-BIB0040|cit40","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.3"},{"key":"10.1002\/14651858.CD015824.pub2-BIB0041|cit41","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2024"},{"issue":"9","key":"10.1002\/14651858.CD015824.pub2-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD015824.pub2-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/hr.2014.28","article-title":"Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension","volume":"37","author":"Zhuang","year":"2014","journal-title":"Hypertension Research"},{"issue":"5","key":"10.1002\/14651858.CD015824.pub2-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.ihj.2021.07.007","article-title":"A randomized, double-blind, placebo-controlled study to evaluate sildenafil, ambrisentan combination therapy in pulmonary hypertension, particularly of Eisenmenger syndrome","volume":"73","author":"Mohammed","year":"2021","journal-title":"Indian Heart Journal"},{"issue":"2","key":"10.1002\/14651858.CD015824.pub2-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1183\/13993003.02044-2014","article-title":"Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension","volume":"46","author":"McLaughlin","year":"2015","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD015824.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/jrsm.1287","article-title":"Machine learning for identifying randomized controlled trials: an evaluation and practitioner's guide","volume":"9","author":"Marshall","year":"2018","journal-title":"Research Synthesis Methods"},{"issue":"11","key":"10.1002\/14651858.CD015824.pub2-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1164\/rccm.200410-1411OC","article-title":"Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study","volume":"171","author":"Wilkins","year":"2005","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"25","key":"10.1002\/14651858.CD015824.pub2-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1056\/NEJMra2000348","article-title":"Pulmonary arterial hypertension","volume":"385","author":"Hassoun","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD015824.pub2-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1378\/chest.12-3023","article-title":"Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis","volume":"144","author":"Frost","year":"2013","journal-title":"Chest"},{"issue":"1","key":"10.1002\/14651858.CD015824.pub2-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00228-007-0408-z","article-title":"Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil","volume":"64","author":"Burgess","year":"2008","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD015824.pub2-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1365-2125.2005.02383.x","article-title":"Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension","volume":"60","author":"Paul","year":"2005","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD015824.pub2-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12872-017-0674-3","article-title":"Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial","volume":"17","author":"Vizza","year":"2017","journal-title":"BioMed Central Cardiovascular Disorders"},{"issue":"11","key":"10.1002\/14651858.CD015824.pub2-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s40261-019-00841-1","article-title":"Effect of combination therapy of endothelin receptor antagonist and phosphodiesterase-5 inhibitor on clinical outcome and pulmonary haemodynamics in patients with pulmonary arterial hypertension: a meta-analysis","volume":"39","author":"Kirtania","year":"2019","journal-title":"Clinical Drug Investigation"},{"issue":"2","key":"10.1002\/14651858.CD015824.pub2-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.chest.2016.03.031","article-title":"Efficacy and safety of pulmonary arterial hypertension-specific therapy in pulmonary arterial hypertension: a meta-analysis of randomized controlled trials","volume":"150","author":"Liu","year":"2016","journal-title":"Chest"},{"key":"10.1002\/14651858.CD015824.pub2-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"102144","DOI":"10.1016\/j.pupt.2022.102144","article-title":"Efficacy and safety of sequential combination therapy for pulmonary arterial hypertension: a meta-analysis of randomized-controlled trials","volume":"76","author":"Tan","year":"2022","journal-title":"Pulmonary Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD015824.pub2-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"i2089","DOI":"10.1136\/bmj.i2089","article-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines","volume":"353","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD015824.pub2-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.chest.2019.07.005","article-title":"Point: should initial combination therapy be the standard of care in pulmonary arterial hypertension? Yes","volume":"156","author":"Humbert","year":"2019","journal-title":"Chest"},{"issue":"6","key":"10.1002\/14651858.CD015824.pub2-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.chest.2019.07.004","article-title":"Counterpoint: should initial combination therapy be the standard of care in pulmonary arterial hypertension? No","volume":"156","author":"Channick","year":"2019","journal-title":"Chest"},{"issue":"2","key":"10.1002\/14651858.CD015824.pub2-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.chest.2017.08.1159","article-title":"Ethnicity in pulmonary arterial hypertension: possibilities for novel phenotypes in the age of personalized medicine","volume":"153","author":"Medrek","year":"2018","journal-title":"Chest"},{"issue":"2","key":"10.1002\/14651858.CD015824.pub2-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"e12090","DOI":"10.1002\/pul2.12090","article-title":"Real-world treatment patterns, healthcare resource utilization, and cost among adults with pulmonary arterial hypertension in the United States","volume":"12","author":"Pizzicato","year":"2022","journal-title":"Pulmonary Circulation"},{"issue":"5","key":"10.1002\/14651858.CD015824.pub2-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40273-015-0366-8","article-title":"Cost effectiveness of first-line oral therapies for pulmonary arterial hypertension: a modelling study","volume":"34","author":"Coyle","year":"2016","journal-title":"PharmacoEconomics"},{"issue":"6","key":"10.1002\/14651858.CD015824.pub2-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.healun.2010.11.009","article-title":"Pulmonary arterial hypertension and response to tadalafil (PHIRST) study group. Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension","volume":"30","author":"Barst","year":"2011","journal-title":"Journal of Heart and Lung Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD015824.pub2-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jacc.2023.10.045","article-title":"Randomized trial of macitentan\/tadalafil single-tablet combination therapy for pulmonary arterial hypertension","volume":"83","author":"Gr\u00fcnig","year":"2024","journal-title":"Journal of the American College of Cardiology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:50:42Z","timestamp":1788137442000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD015824.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":63,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd015824.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,4]]}}}